RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, DOSE RESPONSE (RPCDBDR) TRIAL OF CTS-1027, AN INHIBITOR OF MATRIX METALLOPROTEASES (MMPS) IN PATIENTS WITH HCV WHO HAD FAILED PRIOR THERAPIES

Category Primary study
JournalJOURNAL OF HEPATOLOGY
Year 2010
This article has no abstract
Epistemonikos ID: ea5ca9e18ecff4c54b341328f8c23a4fdc60e847
First added on: Feb 28, 2025